Results 121 to 130 of about 17,710 (254)

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

Dupilumab‐Associated Palmar Erythema Successfully Treated With Fluconazole

open access: yes
Australasian Journal of Dermatology, EarlyView.
Katina J. Selvaraj, Geoffrey Lee
wiley   +1 more source

Codfish Oral Immunotherapy in Children Aged 2–10: Randomized Placebo‐Controlled Study

open access: yesAllergy, EarlyView.
Codfish OIT significantly increased desensitization in children with fish allergy (43% vs. 11% placebo, p = 0.003), with 69% achieving 10‐fold threshold increases versus 26% in placebo (p = 0.0003). Sustained unresponsiveness remained limited (23% vs. 9%, p = 0.332). Treatment demonstrated acceptable safety with predominantly mild reactions and reduced
Agnes Sze‐yin Leung   +9 more
wiley   +1 more source

A Case for Anti‐IgE Vaccination

open access: yesAllergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff   +3 more
wiley   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

open access: yesDermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer   +11 more
doaj   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

open access: yesAllergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang   +37 more
wiley   +1 more source

Pronóstico y evolución de la rinosinusitis crónica poliposa intervenida mediante cirugía endoscópica nasosinusal según fenotipos y endotipos [PDF]

open access: yes, 2019
Se realiza un estudio observacional de seguimiento desarrollado en el Hospital Clínico Universitario de Valladolid. La muestra consta de 20 pacientes intervenidos de rinosinusitis crónica poliposa mediante cirugía endoscópica nasosinusal (CENS) entre ...
Rivas González, Juan
core  

Adverse effects of dupilumab in a child with atopic dermatitis: A case report of anaphylaxis and literature review

open access: yesAllergy Medicine
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. It usually develops in childhood and may persist into adulthood. Dupilumab is a fully human monoclonal antibody directed against interleukin-4R-alpha, the common chain ...
Jing Zhang   +4 more
doaj   +1 more source

Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study [PDF]

open access: yesLaryngoscope Investig Otolaryngol
In the control group, 14% experienced at least one episode of ABRS. In the biologic‐exposed group, only 6% had an ABRS episode. This difference was shown to be statistically significant, reflecting a strong protective association biologics have on ABRS episodes.
Zheng W   +4 more
europepmc   +2 more sources

Interleukin‐22 and Interleukin‐18 as Potential Blood Biomarkers in Dupilumab‐Treated Atopic Dermatitis

open access: yes
Allergy, EarlyView.
Ayano Fukushima‐Nomura   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy